North America Minimal Residual Disease (MRD) Testing 麻豆原创 2021-2031 by Offering , Application , Technology , End User , and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0522038

Publication Date:

May 31, 2022

Pages:

108

Publisher:

Grace 麻豆原创 Data

Countries:

North America [1]

USD 2,980.00

Diseases [2]

Diagnostics [3]

Country Overview (Pharma & Healthcare) [4]

Pharma & Healthcare [5]

Description:

North America minimal residual disease (MRD) testing market is projected to grow by 11.1% annually in the forecast period and reach $ 1,056.1 million by 2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 27 tables and 51 figures, this 108-page report 鈥淣orth America Minimal Residual Disease (MRD) Testing 麻豆原创 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire North America minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country.

Based on Offering, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Services
鈥� Test Kits & Consumables

Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Non-Hodgkin's Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
鈥� Multiple Myeloma (MM)
鈥� Acute Lymphoblastic Leukemia (ALL)
鈥� Chronic Lymphoblastic Leukemia (CLL)
鈥� Acute Myeloid Leukemia (AML)
鈥� Chronic Myeloid Leukemia (CML)
鈥� Hodgkin's Lymphoma (HL)
鈥� Solid Tumor
鈥� Other Applications

By Technology, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Flow Cytometry
鈥� Polymerase Chain Reaction (PCR)
鈥� Next-Generation Sequencing (NGS)
鈥� Other Technologies

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Hospitals and Clinics
鈥� Research Institutions
鈥� Diagnostic Laboratories
鈥� Other End Users

Geographically, the following national/local markets are fully investigated:
鈥� U.S.
鈥� Canada
鈥� Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 22
2.2 Major Growth Drivers 24
2.3 麻豆原创 Restraints and Challenges 30
2.4 Emerging Opportunities and 麻豆原创 Trends 33
2.5 Porter鈥檚 Fiver Forces Analysis 37
3 Segmentation of North America 麻豆原创 by Offering 41
3.1 麻豆原创 Overview by Offering 41
3.2 Services 43
3.3 Test Kits & Consumables 44
4 Segmentation of North America 麻豆原创 by Application 45
4.1 麻豆原创 Overview by Application 45
4.2 Non-Hodgkin鈥檚 Lymphoma (NHL) 47
4.2.1 DLBCL 49
4.2.2 Marginal Zone Lymphoma 50
4.2.3 Follicular Lymphoma 51
4.2.4 Peripheral T-cell Lymphoma 52
4.2.5 Mantle Cell Lymphoma 53
4.2.6 Other NHLs 54
4.3 Multiple Myeloma (MM) 55
4.4 Acute Lymphoblastic Leukemia (ALL) 56
4.5 Chronic Lymphoblastic Leukemia (CLL) 57
4.6 Acute Myeloid Leukemia (AML) 58
4.7 Chronic Myeloid Leukemia (CML) 59
4.8 Hodgkin鈥檚 Lymphoma (HL) 60
4.9 Solid Tumor 61
4.10 Other Applications 62
5 Segmentation of North America 麻豆原创 by Technology 63
5.1 麻豆原创 Overview by Technology 63
5.2 Flow Cytometry 65
5.3 Polymerase Chain Reaction (PCR) 66
5.4 Next-Generation Sequencing (NGS) 67
5.5 Other Technologies 68
6 Segmentation of North America 麻豆原创 by End User 69
6.1 麻豆原创 Overview by End User 69
6.2 Hospitals and Clinics 71
6.3 Research Institutions 72
6.4 Diagnostic Laboratories 73
6.5 Other End Users 74
7 North America 麻豆原创 2021-2031 by Country 75
7.1 Overview of North America 麻豆原创 75
7.2 U.S. 78
7.3 Canada 81
7.4 Mexico 83
8 Competitive Landscape 85
8.1 Overview of Key Vendors 85
8.2 New Product Launch, Partnership, Investment, and M&A 89
8.3 Company Profiles 90
Adaptive Biotechnologies Corporation 90
ArcherDX, Inc. (Invitae Corporation) 92
Arup Laboratories 93
Asuragen Inc. 94
Bio-Rad Laboratories, Inc. 95
Cergentis B.V. 96
Guardant Health 97
ICON plc 98
Inivata Ltd. 99
Invivoscribe, Inc. 100
Laboratory Corporation of America Holdings 101
Mission Bio, Inc. 102
Natera, Inc. 103
NeoGenomics Laboratories, Inc. 104
Opko Health, Inc. 105
Quest Diagnostics Incorporated 106
Sysmex Corporation 107
RELATED REPORTS 108

Companies Mentioned:

Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.